Select Premarket Movers
Upside:
- CIG +16% (strength attributed to increased potential for conservative, pro-business/market friendly administration in Brazil)
- GOL +15% (guides Q3 operational cash flow BRL450-500M; EBITDA Margin 11.0-11.5%)
- PBR +15% (multiple broker upgrades)
- BBD +11% (strength attributed to increased potential for conservative, pro-business/market friendly administration in Brazil)
- TTPH +11% (announces presentation of positive data from Phase 3 trials of XERAVA (eravacycline) and Multiple-Ascending dose trial of TP-6076 at IDWeek 2018)
- ITUB +10% (strength attributed to increased potential for conservative, pro-business/market friendly administration in Brazil)
- SBS +10% (strength attributed to increased potential for conservative, pro-business/market friendly administration in Brazil)
- EWZ +9.5% (strength attributed to increased potential for conservative, pro-business/market friendly administration in Brazil)
- PYX +9.1% (momentum) - GGB +6.4% (strength attributed to increased potential for conservative, pro-business/market friendly administration in Brazil)
- MTEM +4.9% (initiated with Buy at Laidlaw)
- ARNC +3.6% (said that Blackstone, Carlyle Group, Onex Corp and CPPIB form consortium for joint bid) - GE +2.4% (Barclays broker upgrade)
- VALE +2.4% (strength attributed to increased potential for conservative, pro-business/market friendly administration in Brazil)
- TRI +1.5% (outlines steps to complete the return of $10B to Shareholders; Raises Quarterly dividend 1.4% to $0.35 from $0.345 (indicated yield 3%))
Downside:
- BECN -4.0% (Williams Blair broker downgrade)
- IRBT -3.1% (Piper Jaffray/Simmons broker downgrade)
- ESV -2.2% (RDC to merge with ESV in all-stock deal valued at $3.9B)
- RDC -1.5% (RDC to merge with ESV in all-stock deal valued at $3.9B)